Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be...